Fund Details
Overview
Investment portfolio
13rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
Degron Therapeutics | May 2026Participated | $40 MSeries A | |
BridGene Biosciences | Oct 2025Participated | $28 MSeries B | |
Atom Bioscience & Pharmaceutical | Jan 2022Led | $45 MSeries C | |
Harbour Biomed | Jul 2020Participated | $103 MSeries C | |
Lachesis | Jan 2020Led | $22 MSeries B | |
CF PharmTech | Jan 2020Participated | $90 MSeries E | |
Jianke | Sep 2018Led | $130 MSeries B | |
Innovative Cellular Therapeutics | Apr 2018Participated | $25 MOther Equity | |
Shanghai Henlius Biotech | Jan 2018Led | $190 MOther Equity | |
Annoroad | Nov 2017Led | $105 MSeries C | |
Wellem | Sep 2017Led | $30 MSeries B | |
Akeso Biopharma | Aug 2017Led | $45 MSeries B | |
Degron Therapeutics | May 2026Participated | $40 MSeries A | |
BridGene Biosciences | Oct 2025Participated | $28 MSeries B | |
Atom Bioscience & Pharmaceutical | Jan 2022Led | $45 MSeries C | |
Harbour Biomed | Jul 2020Participated | $103 MSeries C | |
Lachesis | Jan 2020Led | $22 MSeries B | |
CF PharmTech | Jan 2020Participated | $90 MSeries E | |
Jianke | Sep 2018Led | $130 MSeries B | |
Innovative Cellular Therapeutics | Apr 2018Participated | $25 MOther Equity | |
Shanghai Henlius Biotech | Jan 2018Led | $190 MOther Equity | |
Annoroad | Nov 2017Led | $105 MSeries C | |
Wellem | Sep 2017Led | $30 MSeries B | |
Akeso Biopharma | Aug 2017Led | $45 MSeries B |
13 Items
13
Items
...
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 0 | 1 |
| Series B | 5 | 1 |
| Series C+ | 2 | 2 |
| Other Equity | 1 | 1 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jan '17 | 1 |
| Feb '17 | 0 |
| Mar '17 | 0 |
| Apr '17 | 0 |
| May '17 | 0 |
| Jun '17 | 0 |
| Jul '17 | 0 |
| Aug '17 | 1 |
| Sep '17 | 1 |
| Oct '17 | 0 |
| Nov '17 | 1 |
| Dec '17 | 0 |
| Jan '18 | 1 |
| Feb '18 | 0 |
| Mar '18 | 0 |
| Apr '18 | 1 |
| May '18 | 0 |
| Jun '18 | 0 |
| Jul '18 | 0 |
| Aug '18 | 0 |
| Sep '18 | 1 |
| Oct '18 | 0 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 0 |
| Jun '19 | 0 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 2 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 1 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 1 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 1 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 1 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 13 |
| Marketing & Advertising | 1 |
| Manufacturing | 1 |
| Consumer & Lifestyle | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 1 |
| $25M-$50M | 7 |
| $50M-$100M | 1 |
| $100M-$250M | 4 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| China | 12 |
| United States | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Lapam Capital | 2 |
| SBCVC | 2 |
| Shenzhen Capital Group | 2 |
| AEF Greater Bay Area Fund | 1 |
| Bayland Capital | 1 |
| CMB International | 1 |
| Country Garden Venture Capital | 1 |
| CR-CP Life Science Fund | 1 |
| Crescent Point | 1 |
| CSPC & Growth | 1 |
| Efung Capital | 1 |
| Finnova Capital | 1 |
| Fortune Capital | 1 |
| Gauge Capital | 1 |
| Grains Valley Venture Capital | 1 |
| HBM Healthcare Investments | 1 |
| Hongshan Capital Group (Sequoia Capital China) | 1 |
| Hudson Bay Capital | 1 |
| Kaitai Capital | 1 |
| Kinghall Ventures | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 8 | 62% |
| Participating | 5 | 38% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 5 | 63% |
| Co-led | 3 | 38% |
